Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy

被引：0

作者：

Christoph, Daniel ^{[1
]}

Girard, N. ^{[2
]}

Smit, H. J. M. ^{[3
]}

Sibille, A. ^{[4
]}

Mcdonald, F. ^{[5
]}

Mornex, F. ^{[6
]}

Garassino, M. C. ^{[7
]}

Filippi, A. R. ^{[8
,9
]}

Peters, S. ^{[10
]}

Field, J. K. ^{[11
]}

Haakensen, V. Drageset ^{[12
]}

Bar, J. ^{[13
]}

Chouaid, C. ^{[14
]}

Bray, V. ^{[15
]}

Kao, S. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[18
]}

Garrido, P. ^{[19
]}

Fietkau, R. ^{[20
]}

机构：

[1] Evang Huyssens Stiftung Essen Huttrop, Evang Kliniken Essen Mitte, Dept Med Oncol Hematol, Essen, Germany

[2] Inst Curie & Montsouris, Inst Thorax, Paris, France

[3] Rijnstate Hosp, Dept Pulm Dis, Arnhem, Netherlands

[4] Ctr Hosp Univ Liege, Dept Pneumol & Allergol, Liege, Belgium

[5] Royal Marsden NHS Fdn Trust, Lung Unit, London, England

[6] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[7] Univ Chicago, Dept Hematol Oncol, Chicago, IL USA

[8] Fdn IRCCS Policlin San Matteo, Radiat Oncol Dept, Pavia, Italy

[9] Univ Pavia, Pavia, Italy

[10] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

[11] Univ Liverpool, Roy Castle Lung Canc Res Programme, Dept Mol & Clin Canc Med, Liverpool, England

[12] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[13] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[14] CHI Creteil, Serv Pneumol, Creteil, France

[15] Liverpool Hosp, Dept Med Oncol, Liverpool, NSW, Australia

[16] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[17] AstraZeneca, Oncol, Med Affairs, Gaithersburg, MD USA

[18] AstraZeneca, Oncol, Med Affairs, Paris, France

[19] Univ Alcala, Hosp Ramon y Cajal, Madrid, Spain

[20] Univ Klinikums Erlangen, Dept Radiat Oncol, Erlangen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

256

引用

页码：151 / 151

页数：1

共 50 条

[41] Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy
Abravan, A.
Horne, A.
van Herk, M.
Price, G.
Faivre-Finn, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S567 - S567
[42] Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC - a retrospective analysis in a real-world setting
Reitnauer, L.
Evers, G.
Christoph, D.
Brueckl, W.
Wiesweg, M.
Glanemann, F.
Webendoerfer, M.
Kropf-Sanchen, C.
Acker, F.
Schuette, W.
Hoffknecht, P.
Kerkhoff, A.
Mohr, M.
Lenz, G.
Frost, N.
Overbeck, T.
Sebastian, M.
Bleckmann, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 229 - 229
[43] PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum -based chemoradiotherapy in patients with unresectable, stage III NSCLC.
Bradley, Jeffrey D.
Nishio, Makoto
Okamoto, Isamu
Newton, Michael David
Trani, Leonardo
Shire, Norah J.
Gu, Yu
Dennis, Philip A.
Lee, Ki Hyeong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Overall Survival with Durvalumab versus Placebo after simultaneous Stage III Chemoradiotherapy NSCLC: Updated Data from the PACIFIC Study
De Wit, M.
Schulz, C.
Laak, E.
Wolff, T.
Rueckert, A.
Faehling, M.
Fischer, J. R.
Reck, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S50 - S50
[45] Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
Agbarya, Abed
Shalata, Walid
Addeo, Alfredo
Charpidou, Andriani
Cuppens, Kristof
Brustugun, Odd Terje
Rajer, Mirjana
Jakopovic, Marco
Marinca, Mihai, V
Pluzanski, Adam
Hiltermann, Jeroen
Araujo, Antonio
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
[46] Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience
Stevens, S.
Nindra, U.
Shahnam, A.
Bray, V.
Pal, A.
Yip, P. Y.
Adam, T.
Nagrial, A.
Lee, J. H.
Boyer, M.
Kao, S. C-H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S989 - S989
[47] Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
Zukin, Mauro
Gondim, Victor
Shimada, Andrea Kazumi
Lima, Ellias Magalhaes e Abreu
Mathias, Clarissa
Barra, Williams Fernandes
William Jr, William Nassib
Padoan, Monica
Bittencourt, Yuri
Yamamura, Rosely
Silva, Carlos Eduardo Baston
Rossato, Leticia de Jesus
Monteiro, Caio de Almeida
Jesus, Rafaela Gomes de
Gossling, Gustavo
Gelatti, Ana Caroline Zimmer
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2024, 50 (06)
[48] Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Naidoo, Jarushka
Antonia, Scott
Wu, Yi-Long
Cho, Byoung Chul
Thiyagarajah, Piruntha
Mann, Helen
Newton, Michael
Faivre-Finn, Corinne
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 657 - 663
[49] Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study
Guan, Song
Sun, Jifeng
Wang, Yuan
Han, Sibei
Chen, Chen
Yue, Dongsheng
Huang, Yubei
Ren, Kai
Wang, Jun
Wang, Jun
Zhao, Lujun
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
[50] Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer
Chu Chia-Hsun
Chiu Tzu-Hsuan
Wang Chin-Chou
Chang Wen-Chen
Huang Allen Chung-Cheng
Liu Chien-Ying
Wang Chih-Liang
Ko Ho-Wen
Chung Fu-Tsai
Hsu Ping-Chih
Guo Yi-Ke
Kuo, Chih-Hsi S.
Yang Cheng-Ta
THORACIC CANCER, 2020, 11 (06) : 1541 - 1549

← 1 2 3 4 5 →